In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Oxford Immunotec Global PLC

www.oxfordimmunotec.com

Latest From Oxford Immunotec Global PLC

Deals Shaping the Medical Industry, January 2018

Derived from Strategic Transactions, Informa’s premium source for tracking life sciences deal activity, the Dealmaking column is a survey of recent health care transactions listed by relevant industry segment – In Vitro Diagnostics, Medical Devices, and Pharmaceuticals – and then categorized by type – Acquisition, Alliance, or Financing. This month’s column covers deals announced in December 2017.

Deals BioPharmaceutical

Lyme Disease: Has Big Pharma Stopped The Clock On A Cure?

Though vastly underreported, new cases of Lyme in the US total more than 300,000 a year; its incidence now exceeds infections for far more visible conditions like HIV. A higher profile for Lyme is hobbled by a slow and distorted institutional response, especially among clinicians who disagree on whether Lyme is one disease or a complex constellation of many – much like cancer, but without the commitment.

BioPharmaceutical Infectious Diseases

Deals Shaping The Medical Industry, September 2017

Derived from Strategic Transactions, Informa’s premium source for tracking life sciences deal activity, the Dealmaking column is a survey of recent health care transactions listed by relevant industry segment – In Vitro Diagnostics, Medical Devices, and Pharmaceuticals – and then categorized by type – Acquisition, Alliance, or Financing. This month’s column covers deals announced in August 2017.

Deals Medical Device

Oxford Immunotec Hires Koski To Forge Investor Ties

Oxford Immunotec has appointed Karen Koski as its head of strategy and investor relations. Koski joins the company as it prepares to launch this year two new tests from its T-spot platform.

Appointments Immunology
See All

Company Information

  • Industry
  • In Vitro Diagnostics
    • Chemistry, Immunoassay
    • Cytology
  • Laboratory Testing Services
  • Therapeutic Areas
  • Immune Disorders
  • Infectious & Viral Diseases
  • Alias(es)
  • Oxford Immunotec Ltd.
  • Ownership
  • Public
  • Headquarters
  • Worldwide
    • Europe
      • Western Europe
        • UK
  • Parent & Subsidiaries
  • Oxford Immunotec Global PLC
  • Senior Management
  • Peter Wrighton-Smith, PhD, CEO
    Matthew McLaughlin, CFO
    Stefan Linn, PhD, COO
    Richard Wenstrup, MD, CMO
  • Contact Info
  • Oxford Immunotec Global PLC
    Phone: (44) 1235 442 780
    115D Innovation Dr., Milton Pk.
    Abingdon, OX14 4RZ
    UK
Advertisement
Advertisement
UsernamePublicRestriction

Register